| Market Cap | 118.84M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -50.22M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
| Sales | 53.26M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 5.00% |
| Dividend | N/A | Price/Book | 3.12 | EPS next 5Y | - | 52W High Chg | -35.00% |
| Recommedations | - | Quick Ratio | 0.93 | Shares Outstanding | 4.77B | 52W Low Chg | 250.00% |
| Insider Own | 93.21% | ROA | -34.76% | Shares Float | 239.13M | Beta | 1.34 |
| Inst Own | 0.12% | ROE | -155.90% | Shares Shorted/Prior | -/- | Price | 0.18 |
| Gross Margin | 52.54% | Profit Margin | -94.29% | Avg. Volume | - | Target Price | - |
| Oper. Margin | -34.15% | Earnings Date | Mar 27 | Volume | 300 | Change | 0.00% |
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.